Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China · Delayed Price · Currency is CNY 20.78
-0.12 (-0.57%)
Feb 13, 2026, 3:00 PM CST
Nanjing Vazyme Biotech Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -29.64 | -18.09 | -70.96 | 594.25 | 678.29 | 821.73 |
Depreciation & Amortization | 138.01 | 138.01 | 157.38 | 122.1 | 55.28 | 13.73 |
Other Amortization | 75.31 | 75.31 | 78.26 | 94.83 | 27.92 | 9.71 |
Loss (Gain) From Sale of Assets | 2.1 | 2.1 | -5.67 | 0.22 | -0.01 | 0.05 |
Asset Writedown & Restructuring Costs | 1.8 | 1.8 | 1.73 | 236.85 | 2.35 | 1.71 |
Loss (Gain) From Sale of Investments | -59.9 | -59.9 | -50.92 | -88.02 | -29.81 | -14.94 |
Provision & Write-off of Bad Debts | 20.26 | 20.26 | -7.27 | 91.68 | 12.08 | 10.46 |
Other Operating Activities | 233.17 | 57.09 | 165.4 | 333.07 | 46.61 | 54.99 |
Change in Accounts Receivable | -188.25 | -188.25 | 534.67 | -682.89 | -133.2 | -164.36 |
Change in Inventory | -39.04 | -39.04 | -124.37 | -403.82 | -148.94 | -128.2 |
Change in Accounts Payable | -13 | -13 | -511.13 | 464.58 | 113.78 | 169.23 |
Change in Other Net Operating Assets | 53.56 | 53.56 | 25.28 | 7.37 | 7.47 | 10.62 |
Operating Cash Flow | 154.86 | -9.68 | 152.99 | 735.17 | 616.8 | 803.55 |
Operating Cash Flow Growth | 116.31% | - | -79.19% | 19.19% | -23.24% | 5185.70% |
Capital Expenditures | -40.72 | -74.9 | -232.9 | -962.86 | -261.96 | -152.54 |
Sale of Property, Plant & Equipment | 1.56 | 2.47 | 13.48 | 15.59 | 2.73 | 0.17 |
Cash Acquisitions | - | - | - | -117.93 | - | - |
Investment in Securities | -145.62 | 395.03 | -726.65 | 51.07 | -1,195 | -794.95 |
Other Investing Activities | 67.13 | 52.6 | 45.42 | 61.7 | 26.15 | 14.29 |
Investing Cash Flow | -117.64 | 375.21 | -900.65 | -952.44 | -1,428 | -933.03 |
Short-Term Debt Issued | - | 1,105 | 1,461 | 372 | - | 29.51 |
Long-Term Debt Issued | - | 0.02 | 0.56 | - | - | - |
Total Debt Issued | 959.42 | 1,105 | 1,462 | 372 | - | 29.51 |
Short-Term Debt Repaid | - | -1,723 | -638.79 | -156.41 | -39.56 | -64 |
Total Debt Repaid | -760.49 | -1,723 | -638.79 | -156.41 | -39.56 | -64 |
Net Debt Issued (Repaid) | 198.92 | -618.8 | 822.77 | 215.59 | -39.56 | -34.49 |
Issuance of Common Stock | 38.5 | 38.5 | - | - | 2,129 | 300 |
Repurchase of Common Stock | -104.4 | -104.4 | -20.01 | - | - | - |
Common Dividends Paid | -102.89 | -80.36 | -533.33 | -132.24 | -4.45 | -1.45 |
Other Financing Activities | 41.07 | -21.21 | -19.63 | -4.3 | -15.2 | -2.86 |
Financing Cash Flow | 71.21 | -786.27 | 249.8 | 79.05 | 2,070 | 261.2 |
Foreign Exchange Rate Adjustments | -1.38 | -4.24 | 1.46 | 5.04 | -2.32 | -3.9 |
Net Cash Flow | 107.05 | -424.98 | -496.4 | -133.18 | 1,256 | 127.83 |
Free Cash Flow | 114.14 | -84.58 | -79.91 | -227.69 | 354.84 | 651.01 |
Free Cash Flow Growth | 1606.12% | - | - | - | -45.49% | - |
Free Cash Flow Margin | 8.49% | -6.14% | -6.21% | -6.38% | 18.99% | 41.61% |
Free Cash Flow Per Share | 0.34 | -0.23 | -0.20 | -0.57 | 0.98 | 1.83 |
Cash Income Tax Paid | 31.45 | 61.14 | 99.76 | 146.72 | 175.67 | 152.17 |
Levered Free Cash Flow | 162.57 | -105.83 | -102.16 | -451.34 | 181.59 | 403.29 |
Unlevered Free Cash Flow | 177.14 | -88.79 | -80.25 | -443.54 | 184 | 403.94 |
Change in Working Capital | -226.25 | -226.25 | -114.95 | -649.81 | -175.9 | -93.88 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.